
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
An interview with Dr. Evan Zynda – an expert in the cell therapy process development and manufacturing workflow – on some of the key areas of innovation within the cell therapy industry and where it’s headed in the future.







